Cliffs Natural Resources Inc. (NYSE:CLF) announced it has been ranked No. 7 on the 2011 Barron's 500 America's Top Companies list. Cliffs was distinguished as the only mining and Natural Resources Company positioned with a top ten ranking. Barron's ranks publicly traded U.S. and Canada-based companies using cash flow return on investment (CFROI) and revenue growth criteria. The publication then grades companies A through F on their performances. Cliffs achieved a grade of A and rated a perfect GPA score of 4.0.
Cliffs Natural Resources Inc., a mining and natural resources company, produces iron ore pellets, lump and fines iron ore, and metallurgical coal.
IHS Inc. (NYSE:IHS) announced that Executive Vice President and Chief Financial Officer Michael J. Sullivan will present an overview of the company at the 39th Annual J.P. Morgan Technology, Media and Telecom Conference on May 17, 2011 at approximately 10:00 a.m. EDT. A live webcast and replay of the IHS presentation will be available, and can be accessed live at http://www.ihs.com/Investor-Relations and for approximately 90 days following the event.
IHS Inc. provides critical information and insight products and services. It offers its products and services in four information domains: Energy, Product Lifecycle, Security, and Environment.
Edwards Lifesciences Corporation (NYSE:EW) will host its Annual Meeting of Stockholders on Thursday, May 12, 2011 beginning at 10:00 a.m. PT (1:00 pm ET) at its corporate headquarters in Irvine, California. A live webcast of the meeting will be available to all interested parties on the Edwards Lifesciences' investor relations website at http://www.edwards.com/InvestorRelations/EventCalendar.htm. A replay of the webcast can be accessed at this site approximately one hour after the conclusion of the live event and will be available for 30 days after the meeting.
Edwards Lifesciences Corporation provides products and technologies designed to treat advanced cardiovascular diseases.
Power3 Medical Products, Inc (PWRM)
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease).
Power3 Medical Products, Inc. applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 Medical Products, Inc. has developed a portfolio of products including BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual's proteins to detect the presence of disease, a patient's disease progression, a patient's response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.
Parkinson's disease is a chronic neurodegenerative disease, the second most prevalent such disorder after Alzheimer's disease. It is a slowly progressive disease caused by the death of small clusters of cells in the midbrain that results in reduction of a critical neurotransmitter called dopamine, the chemical messenger responsible for coordinated muscle movement.
Power3 Medical Products, Inc use NuroPro Blood Test as diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer's disease, ALS (Lou Gehrig's disease), and Parkinson's disease. Early detection of these diseases would allow physicians to intervene at an early stage to delay disease progression, potentially allowing patients to outlive their debilitating symptoms.
For more information, please visit their website: http://www.power3medical.com
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. BestOtc.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://bestotc.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold BestOTC.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB)